share_log

12 Health Care Stocks Moving In Monday's After-Market Session

Benzinga ·  May 21 04:31

Gainers

  • Larimar Therapeutics (NASDAQ:LRMR) stock increased by 23.6% to $8.99 during Monday's after-market session. The company's market cap stands at $573.5 million.
  • GT Biopharma (NASDAQ:GTBP) stock rose 6.53% to $8.31. The company's market cap stands at $11.4 million. As per the press release, Q1 earnings came out 3 days ago.
  • DermTech (NASDAQ:DMTK) shares moved upwards by 5.52% to $0.38. The market value of their outstanding shares is at $13.2 million. As per the news, the Q1 earnings report came out 4 days ago.
  • BiomX (AMEX:PHGE) shares rose 5.38% to $0.36. The company's market cap stands at $19.8 million.
  • Sharecare (NASDAQ:SHCR) shares rose 4.99% to $0.88. The market value of their outstanding shares is at $317.7 million.
  • Inotiv (NASDAQ:NOTV) stock moved upwards by 4.89% to $1.93. The market value of their outstanding shares is at $49.7 million. As per the press release, Q2 earnings came out 3 days ago.

Losers

  • NovaBay Pharmaceuticals (AMEX:NBY) shares fell 9.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $5.9 million.
  • Sharps Technology (NASDAQ:STSS) stock declined by 7.26% to $0.23. The market value of their outstanding shares is at $3.6 million. The company's, Q1 earnings came out 4 days ago.
  • Scorpius Holdings (AMEX:SCPX) shares decreased by 5.88% to $0.15. The company's market cap stands at $5.4 million.
  • Cadrenal Therapeutics (NASDAQ:CVKD) stock declined by 5.53% to $0.41. The company's market cap stands at $6.5 million.
  • Turnstone Biologics (NASDAQ:TSBX) stock declined by 4.76% to $2.73. The company's market cap stands at $63.2 million.
  • Jin Medical International (NASDAQ:ZJYL) stock fell 4.64% to $2.92. The company's market cap stands at $456.8 million.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment